Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Basal Cell 18Pancreatic Neoplasms 4Neoplasms 4Medulloblastoma 3Stomach Neoplasms 2Skin Neoplasms 2Ovarian Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Basal Cell Nevus Syndrome 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Solid Cancers 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pancreatic Diseases 1Osteosarcoma 1Odontogenic Cysts 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1Multiple Myeloma 1

Interventions

Gemcitabine 79Cisplatin 56pembrolizumab 32Paclitaxel 28Carboplatin 24Docetaxel 19Radiotherapy 17Mitomycin 16Doxorubicin 15atezolizumab 14BCG Vaccine 14Nivolumab 13Cystectomy 13Filgrastim 11vinflunine 10Methotrexate 10Vinblastine 9Fluorouracil 95-aminolevulinic acid hexyl ester 9Sunitinib 7Early Intervention, Educational 7durvalumab 6avelumab 6Taxes 6Methods 6Cystoscopy 6Albumin-Bound Paclitaxel 6enfortumab vedotin 5Trastuzumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urinary Bladder Neoplasms × HhAntag691 × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡